Chronic disease long-term drug prevention trials: Lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)

Alzheimer's and Dementia

Volumn 4, Issue 1 SUPPL. 1, 2008, Pages

  Meinert, Curtis L ^a   Breitner, John C S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELEBRIX; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EDITORIAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LONG TERM CARE; MORTALITY; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 38049179306     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.10.007     Document Type: Editorial

References (40)

1. Tschanz J.T., Corcoran C., Skoog I., Khachaturian A.S., Herrick K.M., Hayden K.L.M., et al. Dementia: the leading predictor of death after age 85-the Cache County Study. Neurology 62 (2004) 1156-1162
2. Aevarsson O., Svanborg A., and Skoog I. Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Arch Neurol 55 (1998) 1226-1232
3. Fredrickson D.S. The field trial: some thoughts on the indispensable ordeal. Bull NY Acad Med 44 (1968) 985-993
4. Meinert C.L., Gilpin A.K., Ünalp A., and Dawson C. Gender representation in trials. Control Clin Trials 21 (2000) 462-475
5. Meinert C.L., and Gilpin A.K. Estimation of gender bias in clinical trials. Stat Med 20 (2000) 1153-1164
6. Martin K.M., Meinert C.L., Breitner J.C.S., and ADAPT Research Group. Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clin Trials 23 (2002) 93-99
7. Solomon S.D., McMurray J.J.V., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Investigators: cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
8. ADAPT Research Group. Cardiovascular and cerebrovascular results from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1 (2006) e33
9. ADAPT Steering Committee. Statement for the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee (2005) (read by C. Lyketsos). February 18
10. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., et al. Mild cognitive impairment - Beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Inter Med 256 (2004) 240-246
11. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome (erratum in Arch Neurol 1999;56:760). Arch Neurol 56 (1999) 303-308
12. Petersen R., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
13. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., et al. A randomized, doubleblind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
14. In 't Veld B., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 (2001) 1515-1521
15. Zandi P.P., Anthony J., Hayden K.M., Mehta K., Mayer L., Breitner J.C., et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59 (2002) 880-886
16. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68 (2007) 1800-1808
17. Peto R., Pike M.C., and Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I-introduction and design. Br J Cancer 34 (1976) 585-612
18. Peto R., Collins R., and Gray R. Large-scale randomized evidence: large, simple trials and overview of trials. J Clin Epidemiol 48 (1995) 23-40
19. Physicians' Health Study Research Group Steering Committee. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
20. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
21. Rehman H.U. Under-representation of the elderly in clinical trials. Eur J Intern Med 16 (2005) 385-386
22. Schmucker D.L., and Vesell E.S. Are the elderly underrepresnted in clinical drug trials. J Clin Pharmacol 39 (1999) 1103-1108
23. Levine C., Faden R., Grady C., Hammerschmidt D., Eckenwiler L., Surgarman J., et al. The limitations of "vulnerability" as a protection for human research participants. Am J Bioethics 4 (2004) 44-49
24. Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for biomedical research involving human subjects (2002), CIOMS, Geneva
25. Neaton J.D., Grimm R.H., Cutler J.A., and MRFIT Research Group. Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). Control Clin Trials 8 (1987) 41S-53S
26. Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial (HPT): design, methods, and baseline results. Control Clin Trials 10 Suppl (1989) 1S-117S
27. Coronary Drug Project Research Group. The Coronary Drug Project: design, methods, and baseline results. Circulation 47 Suppl 1 (1979) I-1-I-50
28. Buckwald H., Matts J.P., Hansen B.J., Long J.M., and Fitch L.L. Program on Surgical Control of the Hyperlipidemias (POSCH): recruitment experience. Control Clin Trials 8 Suppl 4 (1987) 94S-104S
29. Buckwald H., Matts J.P., Fitch L.L., Varco R.L., Campbell G.S., Pearce M., et al. Program on the Surgical Control of the Hyperlipidemias (POSCH): design and methodology. POSCH Group. J Clin Epidemiol 42 (1989) 1111-1127
30. Silverman J.M., Smith C.J., Marin D.B., Mohs R.C., and Propper C.B. Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry 60 (2003) 190-197
31. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 248 (1982) 1445-1477
32. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
33. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program: I-reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242 (1979) 2562-2571
34. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3294
35. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
36. The Women's Health Initiative Steering Committee. Effects of conjugated estrogen in postmenopausal women with hysterectomy. JAMA 291 (2004) 1701-1712
37. University Group Diabetes Program Research Group. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I-design, methods, and baseline characteristics. Diabetes 19 Suppl 2 (1970) 747-783
38. Martin B.K., and Meinert C.L. The case against "firewalls" in academic coordinating centers. Control Clin Trials 23 (2003) 91s
39. Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancers and other cancers in male smokers. N Engl J Med 330 (1994) 1029-1035
40. Bowen D.J., Thornquist M., Anderson K., Barnett M., Powell C., Goodman G., et al. Stopping the active intervention: CARET. Control Clin Trials 24 (2003) 39-50